Serge Leyvraz
Charité Hospital, Berlin, Germany · Centre Hospitalier Universitaire Vaudois
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Serge Leyvraz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:58 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06246149 · Adjuvant Tebentafusp in High Risk Ocular MelanomaEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · Uveal Melanoma · principal investigator
- Ph1NCT00324623 · Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic MelanomaProf. Serge Leyvraz · completed · Melanoma (Skin) · study chair
- Ph3NCT00110123 · Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye MelanomaEuropean Organisation for Research and Treatment of Cancer - EORTC · terminated · Intraocular Melanoma, Metastatic Cancer · study chair
- Ph2NCT00002526 · Chemotherapy in Treating Patients With Advanced SarcomaSwiss Cancer Institute · completed · Ovarian Cancer, Sarcoma · study chair
- Ph3NCT00011921 · Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung CancerEBMT Solid Tumors Working Party · unknown · Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:58 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- 960 citationsRCR 25.8
- 726 citationsRCR 15.4
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Eur J Cancer · 2006688 citationsRCR 14.8
- Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.J Clin Oncol · 2002651 citationsRCR 14.2
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.Blood · 2006511 citationsRCR 12.1
- 358 citationsRCR 12.4
- 163 citationsRCR 5.4
- The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.Eur J Nucl Med Mol Imaging · 2005155 citationsRCR 4.6
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.Nat Med · 2022150 citationsRCR 9.7
- Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Int J Cancer · 2006144 citationsRCR 3.5